We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Hantavirus Rapid Test Paves Way for Early Outbreak Control

By LabMedica International staff writers
Posted on 29 Feb 2024

Orthohantaviruses, known for their ability to cause hemorrhagic fever with renal syndrome (HFRS) in Eurasia and hantavirus cardiopulmonary syndrome in the Americas, are significant public health concerns due to their high transmission rates and impact on health. More...

These zoonotic pathogens have been the focus of extensive research, particularly for controlling outbreaks and devising intervention strategies. In South Korea's Gyeonggi Province, a notable number of HFRS cases have been reported, highlighting the need for diligent epidemiological surveillance and a deeper understanding of orthohantaviruses' genomic diversity. Now, new research has unveiled the potential of cost-efficient Flongle sequencing for rapid hantavirus genome-based diagnostics and phylogeographical surveillance.

A research team from Korea University College of Medicine (Seoul, South Korea) undertook a study in the Gyeonggi Province to investigate the prevalence, viral loads, and genetic variations of Hantaan orthohantavirus (HTNV). They utilized Flongle sequencing, an innovative and budget-friendly approach, for detecting HTNV genomes, emphasizing the use of the Oxford MinION nanopore sequencer in the field of next-generation sequencing technologies. The team's methodology included capturing rodents and shrews from various areas using live traps, followed by mitochondrial DNA analysis, indirect immunofluorescence antibody tests, and other molecular methods for species identification and virus detection.

During the 2017-2018 surveillance in Gyeonggi Province, a substantial presence of Apodemus agrarius, a common rodent species, was noted. Among these, 12.4% were found to be seropositive for HTNV, indicating the virus's prevalence in the region. The use of Flongle sequencing was key in acquiring full-length genomic sequences from positive samples, achieving high coverage rates and accuracy on par with Illumina sequencing. The study's phylogeographical analysis revealed distinct evolutionary divergence among HTNV's tripartite genomes, with genetic clustering and evolutionary pattern incongruences highlighting the virus's segment-specific evolution.

While the study offers critical insights, the researchers acknowledge limitations like the need for enhanced sensitivity testing of Flongle-based diagnostics and the requirement for broader genomic and epidemiological data in certain endemic areas. This research represents a major advancement in the understanding of orthohantaviruses and sets the stage for more focused strategies to combat HFRS outbreaks. The findings underscore the importance of genomics in disease surveillance and hold promise for improved responses to emerging infectious diseases.

“We developed a rapid and sensitive on-site diagnostic using a nanopore-based Flongle chip with a reasonable cost of around $100. This approach enables virtually whole-genome sequencing of HTNV within 3 hours,” said Prof. Jin-Won Song from Korea University College of Medicine who led the research. "We believe our findings provide important insights into on-site diagnostics, genome-based surveillance, and the evolutionary dynamics of orthohantaviruses to mitigate hantaviral outbreaks in HFRS-endemic areas in the ROK. Our study pioneers the integration of cost-efficient Flongle sequencing into hantavirus diagnostics, offering a rapid and accurate tool for on-site detection. This innovation has the potential to transform how we approach and manage hantavirus outbreaks."

Related Links:
Korea University College of Medicine 


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.